Payment overview · 2025
General Payments
$2,921.21
107 reported records · 27 companies
Healthcare provider profile · identity verified
Kevin A Sugalski, DO
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSTOWN, PA · NPI 1902807647
Verified facts
What the public records show
CMS Open Payments records show Kevin A Sugalski, DO received $2,921.21 in general payments during 2025 across 107 reported records.
PFIZER INC. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $436.37 | 14.9% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $360.39 | 12.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $278.56 | 9.5% | 9 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $246.84 | 8.4% | 8 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $228.99 | 7.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $193.91 | 6.6% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $186.25 | 6.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.25 | 5.1% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.39 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $113.18 | 3.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.37 | 2.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.39 | 2.4% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $69.33 | 2.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.86 | 2.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.15 | 1.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.82 | 1.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.34 | 1.0% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $28.01 | 1.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.52 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.51 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.73 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.44 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.25 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.29 | 0.6% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $17.76 | 0.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.33 | 0.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.98 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,900.99 | 106 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $346.65 | 14 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $246.84 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $235.39 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $228.99 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $228.99 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $186.25 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $177.17 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $169.10 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $136.39 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $113.18 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $96.45 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.37 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.85 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.39 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.55 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.55 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.24 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.17 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 182 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 173 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
173 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 38 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 157 |
| Oxycodone Hcl | Oxycodone Hcl | 456 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 399 | 106 |
| Lisinopril | Lisinopril | 398 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 393 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 67 |
| Lorazepam | Lorazepam | 245 | 38 |
| Metformin Hcl | Metformin Hcl | 245 | 65 |
| Omeprazole | Omeprazole | 245 | 61 |
| Simvastatin | Simvastatin | 233 | 58 |
| Gabapentin | Gabapentin | 232 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 210 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 38 |
| Eliquis | Apixaban | 182 | 38 |
| Alprazolam | Alprazolam | 173 | 28 |
| Farxiga | Dapagliflozin Propanediol | 173 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 37 |
| Jardiance | Empagliflozin | 157 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 33 |
| Furosemide | Furosemide | 122 | 31 |
| Benazepril Hcl | Benazepril Hcl | 116 | 31 |
| Losartan Potassium | Losartan Potassium | 114 | 33 |
| Allopurinol | Allopurinol | 112 | 29 |
| Potassium Chloride | Potassium Chloride | 108 | 26 |
| Glimepiride | Glimepiride | 105 | 28 |
| Ezetimibe | Ezetimibe | 103 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 33 |
| Tramadol Hcl | Tramadol Hcl | 92 | 22 |
| Montelukast Sodium | Montelukast Sodium | 86 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 82 | 19 |
| Chlorthalidone | Chlorthalidone | 79 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 20 |
| Famotidine | Famotidine | 75 | 18 |
| Atenolol | Atenolol | 74 | 18 |
| Sertraline Hcl | Sertraline Hcl | 74 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 22 |
| Clonazepam | Clonazepam | 67 | 13 |
| Meloxicam | Meloxicam | 67 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Celecoxib | Celecoxib | 64 | 18 |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 14 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Ozempic | Semaglutide | 48 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Humalog | Insulin Lispro | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 12 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Prednisone | Prednisone | 30 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,921.21 · 107 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, ELIQUIS, FARXIGA, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Flexitouch Plus, Fluad, Flucelvax, GARDASIL 9, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, Nimbl, OFEV, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, REXULTI, SHINGRIX, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error